This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (356)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Randomized Controlled Trial  • Alert me on articles by topic

A 3-Year Randomized Trial

Joel E. Gallant, MD, MPH; Schlomo Staszewski, MD; Anton L. Pozniak, MD; Edwin DeJesus, MD; Jamal M. A. H. Suleiman, MD; Michael D. Miller, PhD; Dion F. Coakley, PharmD; Biao Lu, PhD; John J. Toole, MD, PhD; Andrew K. Cheng, MD, PhD; for the 903 Study Group

JAMA. 2004;292:191-201.

Context  Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor.

Objective  To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients.

Design, Setting, and Participants  A prospective, randomized, double-blind study conducted at 81 centers in the United States, South America, and Europe from June 9, 2000, to January 30, 2004. A total of 753 patients infected with HIV who were antiretroviral naive were screened and 602 patients entered the study.

Intervention  Patients were randomized to receive either tenofovir DF (n = 299) or stavudine (n = 303), with placebo, in combination with lamivudine and efavirenz.

Main Outcome Measure  Proportion of patients with HIV RNA levels of less than 400 copies/mL at week 48.

Results  In the primary intent-to-treat analysis in which patients with missing data or who added or switched antiretroviral medications before week 48 were considered as failures, the proportion of patients with HIV RNA of less than 400 copies/mL at week 48 was 239 (80%) of 299 in patients receiving tenofovir DF and 253 (84%) of 301 in patients receiving stavudine (95% confidence interval, –10.4% to 1.5%), exceeding the predefined –10% limit for equivalence. However, equivalence was demonstrated in the secondary analyses (HIV RNA <50 copies/mL) at week 48 and through 144 weeks. Virologic failure was associated most frequently with efavirenz and lamivudine resistance. Through 144 weeks, the K65R mutation emerged in 8 and 2 patients in the tenofovir DF and stavudine groups, respectively (P = .06). A more favorable mean change from baseline in fasting lipid profile was noted in the tenofovir DF group at week 144: for triglyceride levels (+1 mg/dL for tenofovir DF [n = 170] vs +134 mg/dL for stavudine [n = 162], P<.001), total cholesterol (+30 mg/dL [n = 170] vs +58 mg/dL [n = 162], P<.001), direct low-density lipoprotein cholesterol (+14 mg/dL [n = 169] vs +26 mg/dL [n = 161], P<.001), and high-density lipoprotein cholesterol (+9 mg/dL [n = 168] vs +6 mg/dL [n = 154], P = .003). Investigator-reported lipodystrophy was less common in the tenofovir DF group compared with the stavudine group (9 [3%] of 299 vs 58 [19%] of 301, P<.001). The number of bone fractures and the renal safety profile were similar between the 2 groups.

Conclusions  Through 144 weeks, the combination of tenofovir DF, lamivudine, and efavirenz was highly effective and comparable with stavudine, lamivudine, and efavirenz in antiretroviral-naive patients. However, tenofovir DF appeared to be associated with better lipid profiles and less lipodystrophy.

Author Affiliations: Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Md (Dr Gallant); Department of Internal Medicine, University Hospital, J.W. Goethe-Universität, Frankfurt, Germany (Dr Staszewski); Department of Genitourinary Medicine, Chelsea and Westminster Hospital, London, England (Dr Pozniak); Infectious Disease Consultants Research Initiative, Altamonte Springs, Fla (Dr DeJesus); Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil (Dr Suleiman); and Gilead Sciences, Foster City, Calif (Drs Miller, Coakley, Lu, Toole, and Cheng).

RELATED LETTER

Tenofovir, Equivalence, and Noninferiority
Jean-Jacques Parienti
JAMA. 2004;292(16):1951.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Treatment of HIV/AIDS: Do the Dilemmas Only Increase?
Merle A. Sande and Allan Ronald
JAMA. 2004;292(2):266-268.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy
Phillips and Hay
J Antimicrob Chemother 2008;62:866-871.
ABSTRACT | FULL TEXT  

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial
Duvivier et al.
J Antimicrob Chemother 2008;62:797-808.
ABSTRACT | FULL TEXT  

A 39-Year-Old Man With HIV-Associated Lipodystrophy
Fuller
JAMA 2008;300:1056-1066.
ABSTRACT | FULL TEXT  

Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects
Van Rompay et al.
Antimicrob. Agents Chemother. 2008;52:3144-3160.
ABSTRACT | FULL TEXT  

Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel
Hammer et al.
JAMA 2008;300:555-570.
ABSTRACT | FULL TEXT  

Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy
Brown
J. Clin. Endocrinol. Metab. 2008;93:2937-2945.
ABSTRACT | FULL TEXT  

The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy
Perez-Molina et al.
J Antimicrob Chemother 2008;62:234-245.
ABSTRACT | FULL TEXT  

Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk Factors
Grunfeld et al.
Circulation 2008;118:e20-e28.
FULL TEXT  

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy
Ananworanich et al.
J Antimicrob Chemother 2008;61:1340-1343.
ABSTRACT | FULL TEXT  

Initial Treatment for HIV Infection -- An Embarrassment of Riches
Hirschel and Calmy
NEJM 2008;358:2170-2172.
FULL TEXT  

Know Your Patient: What Conditions Affect Initial HIV Treatment Success?
Hodder
J Int Assoc Physicians AIDS Care (Chic Ill) 2008;7:S5-S9.
ABSTRACT  

Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection
Samaras
J Antimicrob Chemother 2008;61:238-245.
ABSTRACT | FULL TEXT  

HIV and HIV treatment: effects on fats, glucose and lipids
Gkrania-Klotsas and Klotsas
Br Med Bull 2007;84:49-68.
ABSTRACT | FULL TEXT  

Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis
Bolland et al.
J. Clin. Endocrinol. Metab. 2007;92:4522-4528.
ABSTRACT | FULL TEXT  

Prevalence of chronic kidney disease in Chinese HIV-infected patients
Cheung et al.
Nephrol Dial Transplant 2007;22:3186-3190.
ABSTRACT | FULL TEXT  

Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues
Leon et al.
J Antimicrob Chemother 2007;60:824-830.
ABSTRACT | FULL TEXT  

Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study
Young et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:178-187.
ABSTRACT  

Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir
Rossi et al.
J Antimicrob Chemother 2007;59:666-675.
ABSTRACT | FULL TEXT  

Dyslipidemia in an Asian Population After Treatment for Two Years With Protease Inhibitor-Containing Regimens
Kerr et al.
J Int Assoc Physicians AIDS Care (Chic Ill) 2007;6:36-46.
ABSTRACT  

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors
Rivero et al.
J Antimicrob Chemother 2007;59:342-346.
ABSTRACT | FULL TEXT  

Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs
Paltiel et al.
ANN INTERN MED 2006;145:797-806.
ABSTRACT | FULL TEXT  

In Vitro Human Immunodeficiency Virus Type 1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir and Lamivudine
Margot et al.
Antimicrob. Agents Chemother. 2006;50:4087-4095.
ABSTRACT | FULL TEXT  

High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens
Doualla-Bell et al.
Antimicrob. Agents Chemother. 2006;50:4182-4185.
ABSTRACT | FULL TEXT  

The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
Staszewski et al.
J Antimicrob Chemother 2006;58:1024-1030.
ABSTRACT | FULL TEXT  

In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells
Vidal et al.
Antimicrob. Agents Chemother. 2006;50:3824-3832.
ABSTRACT | FULL TEXT  

Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
Rodriguez et al.
JAMA 2006;296:1498-1506.
ABSTRACT | FULL TEXT  

Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy: Impact on Bone Mineral Density in HIV-Infected Children
Gafni et al.
Pediatrics 2006;118:e711-e718.
ABSTRACT | FULL TEXT  

A novel pattern of lipoaccumulation in HIV-infected men.
Palella et al.
JAMA 2006;296:766-768.
FULL TEXT  

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick et al.
JAMA 2006;296:769-781.
ABSTRACT | FULL TEXT  

Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society-USA Panel
Hammer et al.
JAMA 2006;296:827-843.
ABSTRACT | FULL TEXT  

Metabolic and skeletal complications of HIV infection: the price of success.
Morse and Kovacs
JAMA 2006;296:844-854.
ABSTRACT | FULL TEXT  

Preexposure prophylaxis for HIV: unproven promise and potential pitfalls.
Liu et al.
JAMA 2006;296:863-865.
FULL TEXT  

Antiretroviral treatment of HIV infected adults.
Deeks
BMJ 2006;332:1489-1489.
FULL TEXT  

Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Laessig et al.
NEJM 2006;354:2506-2508.
FULL TEXT  

Key questions in antiretroviral therapy: Italian Consensus Workshop (2005)
Carosi et al.
J Antimicrob Chemother 2006;57:1055-1064.
ABSTRACT | FULL TEXT  

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant et al.
NEJM 2006;354:251-260.
ABSTRACT | FULL TEXT  

Antiretroviral therapy in a thousand patients with AIDS in Haiti.
Severe et al.
NEJM 2005;353:2325-2334.
ABSTRACT | FULL TEXT  

Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection
Hazra et al.
Pediatrics 2005;116:e846-e854.
ABSTRACT | FULL TEXT  

Once-daily antiretroviral therapy: Spanish Consensus Statement
Pulido et al.
J Antimicrob Chemother 2005;56:808-818.
ABSTRACT | FULL TEXT  

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)
Delaunay et al.
J. Virol. 2005;79:9572-9578.
ABSTRACT | FULL TEXT  

Current perspectives on HIV-associated lipodystrophy syndrome
Milinkovic and Martinez
J Antimicrob Chemother 2005;56:6-9.
ABSTRACT | FULL TEXT  

Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol
Latham et al.
J Antimicrob Chemother 2005;56:186-189.
ABSTRACT | FULL TEXT  

Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase
Wainberg et al.
Antimicrob. Agents Chemother. 2005;49:1671-1678.
FULL TEXT  

Therapeutic approaches to combating lipoatrophy: do they work?
Martin and Mallon
J Antimicrob Chemother 2005;55:612-615.
ABSTRACT | FULL TEXT  

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study
Izzedine et al.
Nephrol Dial Transplant 2005;20:743-746.
ABSTRACT | FULL TEXT  

In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase
Parikh et al.
Antimicrob. Agents Chemother. 2005;49:1139-1144.
ABSTRACT | FULL TEXT  

Diminished Replicative Fitness of Primary Human Immunodeficiency Virus Type 1 Isolates Harboring the K65R Mutation
Weber et al.
J. Clin. Microbiol. 2005;43:1395-1400.
ABSTRACT | FULL TEXT  

Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults
Grinspoon and Carr
NEJM 2005;352:48-62.
FULL TEXT  

Tenofovir, Equivalence, and Noninferiority
Parienti
JAMA 2004;292:1951-1951.
FULL TEXT  

Tenofovir vs. d4T
AIDS Clin Care 2004;2004:4-4.
FULL TEXT  

Emtricitabine and Tenofovir: Ready for Prime Time?
JWatch Infect. Diseases 2004;2004:3-3.
FULL TEXT  

Treatment of HIV/AIDS: Do the Dilemmas Only Increase?
Sande and Ronald
JAMA 2004;292:266-268.
FULL TEXT